Recent developments in leishmaniasis vaccine delivery systems

Expert Opinion on Drug Delivery

Volumn 5, Issue 7, 2008, Pages 789-803

  Bhowmick, Sudipta ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Adjuvant; Cationic liposomes; Leishmania; Vaccine; Vaccine delivery systems

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL VACCINE; BCG LEISHMANIA VACCINE; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DNA VACCINE; EMULSIFYING AGENT; FREUND ADJUVANT; INTERLEUKIN 2; LEISHMANIA HOMOLOG OF RECEPTOR FOR ACTIVATED C KINASE; LEISHMANIA VACCINE; LIPOSOME; LIVE VACCINE; MONTANIDE ISA 720; PHOSPHORYL LIPID A; POLOXAMER; RECOMBINANT INTERLEUKIN 2; SAPONIN; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EMULSION; HUMAN; IMMUNOSTIMULATION; INFECTION CONTROL; LEISHMANIASIS; LISTERIA MONOCYTOGENES; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROPIONIBACTERIUM ACNES; REVIEW; SALMONELLA TYPHIMURIUM; SKIN LEISHMANIASIS; TOXOPLASMA GONDII; VACCINATION; VACCINE PRODUCTION; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIASIS; LEISHMANIASIS VACCINES;

EID: 48449089960     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.7.789     Document Type: Review

References (118)

1. World Health Organization [WHO], Leishmaniasis Control homepage. Available from: http://www.who.int/ctd/html/leish.html
2. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology 2006;133(Suppl):S87-112
3. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11:S63-8
4. O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001;18:69-85
5. Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun 1977;16:249-57
6. Weintraub J, Weinbaum FI. The effect of BCG on experimental cutaneous leishmaniasis in mice. J Immunol 1977;118:2288-90
7. Vélez ID, del Pilar Agudelo S, Arbelaez MP, et al. Safety and immunogenicity of a killed Leishmania (L) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000;94:698-703
8. Armijos RX, Weigel MM, Calvopina M, et al. Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004;22(9-10):1320-6
9. Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-9
10. Convit J, Ulrich M, Zerpa O, et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 2003;97:469-72
11. Convit J, Ulrich M, Polegre MA, et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 2004;99:57-62
12. Molano I, Alonso MG, Mirón C, et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 2003;92:1-13
13. Ghosh A, Zhang WW, Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001;20:59-66
14. Misra A, Dube A, Srivastava B, et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001;19:3485-92
15. Kamil AA, Khalil EA, Musa AM, et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003;97(3):365-8
16. Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008;102:58-63
17. Santos WR, Paraguai de Souza E, Palatnik M, Palatnik de Sousa CB. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine 1999;172554-61
18. Santos WR, de Lima VM, de Souza EP, et al. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002;21:30-43
19. Oliveira-Freitas E, Casas CP, Borja-Cabrera GP et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 2006;24:3909-20
20. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 2002;20:3277-84
21. Santos WR, Aguiar IA, Paraguai de Souza E, et al. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 2003;21:4668-76
22. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E, et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004;22:2234-43
23. Aebischer T, Wolfram M, Patzer SI, et al. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000;68:1328-36
24. Webb JR, Campos-Neto A, Ovendale PJ, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998;66(7):3279-89
25. Campos-Neto A, Porrozzi R, Greeson K, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001;69:4103-8
26. Noormohammadi AH, Hochrein H, Curtis JM, et al. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen. Vaccine 2001;19:4043-52
27. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998;4:1409-15
28. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005;21:244-9
29. Coler RN, Skeiky YA, Bernards K, et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002;70:4215-25
30. Skeiky YA, Coler RN, Brannon M, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002;20:3292-303
31. Coler RN, Goto Y, Bogatzki L, et al. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007;75:4648-54
32. Gradoni L, Foglia Manzillo V, Pagano A, et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005;23:5245-51
33. Ghalib H, Modabber F. Consultation meeting on the development of therapeutic vaccines for post-kala azar dermal leishmaniasis. Kinetoplastid Biol Dis 2007;6:7
34. Zimmermann S, Egeter O, Hausmann S, et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998;160:3627-30
35. Walker PS, Scharton-Kersten T, Krieg AM, et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999;96:6970-5
36. Rhee EG, Mendez S, Shah JA, et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002;195:1565-73
37. Flynn B, Wang V, Sacks DL, et al. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect Immun 2005;73:4948-54
38. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617-24
39. Verthelyi D, Gursel M, Kenney RT, et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol 2003;170:4717-23
40. Mendez S, Tabbara K, Belkaid Y, et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect Immun 2003;71:5121-9
41. Wu W, Weigand L, Belkaid Y, Mendez S. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur J Immunol 2006;36:3238-47
42. Connell ND, Medina-Acosta E, McMaster WR, et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 1993;90:11473-7
43. Streit JA, Recker TJ, Donelson JE, Wilson ME. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 2000;94:33-41
44. Yang DM, Fairweather N, Button LL, et al. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990;145:2281-5
45. Soussi N, Milon G, Colle JH, et al. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect Immun 2000;68:1498-506
46. Ramírez JR, Gilchrist K, Robledo S, Sepúlveda, et al. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. Vaccine 2001;20:455-61
47. Solioz N, Blum-Tirouvanziam U, Jacquet R, et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine 1999;18:850-9
48. Masina S, M Gicheru M, Demotz SO, Fasel NJ. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen. J Infect Dis 2003;188:1250-7
49. Spitzer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 1999;17:1298-300
50. Rafati S, Kariminia A, Seyde-Eslami S, et al. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine 2002;20:2439-47
51. Zadeh-Vakili A, Taheri T, Taslimi Y, et al. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinaaes Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine 2004;22:1930-40
52. Stevenson FK. DNA vaccines and adjuvants. Immunol Rev 2004;199:5-8
53. Restifo NP, Ying H, Hwang L, Leitner WW. The promise of nucleic acid vaccines. Gene Ther 2000;7:89-92
54. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 2002;4:23-7
55. + T cells. J Immunol 2000;165:915-24
56. Ruiz JH, Becker I. CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 2007;29:671-8
57. Xu D, Liew FY. Genetic vaccination against leishmaniasis. Vaccine 1994;2:1534-6
58. Ahmed SB, Bahloul C, Robbana C, et al. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 2004;22:1631-9
59. Sjölander A, Baldwin TM, Curtis JM, et al. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998;16:2077-84
60. Handman E, Noormohammadi AH, Curtis JM, et al. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 2000;18:3011-7
61. Dumonteil E, Maria Jesus RS, Javier EO, et al. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 2003;21:2161-8
62. Gurunathan S, Sacks DL, Brown DR, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997;186:1137-47
63. López-Fuertes L, Pérez-Jiménez E, Vila-Coro AJ, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21:247-57
64. Pinto EF, Pinheiro RO, Rayol A, et al. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect Immun 2004;72:4521-7
65. Melby PC, Yang J, Zhao W, et al. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001;69:4719-25
66. Marques-da-Silva EA, Coelho EA, Gomes DC, et al. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol Res 2005;98:67-74
67. Iborra S, Soto M, Carrión J, et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun 2003;71:6562-72
68. Campbell K, Diao H, Ji J, Soong L. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect Immun 2003;71:6270-8
69. Rafati S, Salmanian AH, Taheri T, et al. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001;19:3369-75
70. Iborra S, Soto M, Carrión J, et al. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis. Vaccine 2004;22:3865-76
71. Carrión J, Folgueira C, Alonso C. Immunization strategies against visceral leishmaniasis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine 2008;26:2537-44
72. Ghosh A, Labrecque S, Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001;19:3169-78
73. Zanin FH, Coelho EA, Tavares CA, et al. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect 2007;9:1070-7
74. Sukumaran B, Tewary P, Saxena S, Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 2003;21:1292-9
75. Tewary P, Saxena S, Madhubala R. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis. Vaccine 2006;24:2409-16
76. Basu R, Bhaumik S, Basu JM, et al. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005;174:7160-71
77. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 2005;73:812-9
78. Gamboa-León R, Paraguai de Souza E, Borja-Cabrera GP, et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 2006;24:4863-73
79. Sedegah M, Jones TR, Kaur M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998;95:7648-53
80. Gonzalo RM, del Real G, Rodriguez JR, et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 2002;20:1226-31
81. Tapia E, Pérez-Jiménez E, López-Fuertes L, et al. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003;5:73-84
82. Ramniro MJ, Zárate JJ, Hanke T, et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003;21:2474-84
83. Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect 2006;8:810-22
84. Dondji B, Pérez-Jimenez E, Goldsmith-Pestana K, et al. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 2005;73:5286-9
85. Ramos I, Alonso A, Marcen JM, et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008;26:333-44
86. Lange UG, Mastroeni P, Blackwell JM, Stober CB. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 2004;72:4924-8
87. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006;24:2169-75
88. Rafati S, Nakhaee A, Taheri T, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005;23:3716-25
89. Tewary P, Jain M, Sahani MH, et al. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 2005;191:2130-7
90. Flohé SB, Bauer C, Flohé S, Moll H. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 1998; 28:3800-11
91. Ahuja SS, Reddick RL, Sato N, et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999;163:3890-7
92. Berberich C, Ramírez-Pineda JR, Hambrecht C, et al. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003;170:3171-9
93. Ramírez-Pineda JR, Fröhlich A, Berberich C, Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 2004;172:6281-9
94. Carrión J, Nieto A, Soto M, Alonso C. Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniasis in BALB/c mice. Microbes Infect 2007;9:735-43
95. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252:252
96. Kahl LP, Scott CA, Lelchuk R, et al. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol 1989;142:4441-9
97. Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 1988;140:1274-9
98. Mazumdar T, Anam K, Ali N. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J Parasitol 2005;91:269-74
99. Mazumdar T, Anam K, Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 2004;22:1162-71
100. + T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine 2006;24:1800-10
101. Afrin F, Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 1997;65:2371-7
102. Afrin F, Anam K, Ali N. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J Parasitol 2000;86:730-5
103. Ali N, Afrin F. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J Parasitol 1997;83:70-5
104. Bhowmick S, Ravindran R, Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polariazed Th1 response. Vaccine 2007;25:6544-56
105. Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 2008;76:1003-15
106. Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv Drug Deliv Rev 2000;41:171-88
107. Foged C, Arigita C, Sundblad A, et al. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22:1903-13
108. Chikh GG, Kong S, Bally MB, et al. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 2001;167:6462-70
109. Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 1999;61:233-40
110. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 2001;8:1188-96
111. Gregoriadis G, Bacon A, Caparros-Wanderley W, McCormack B. A role for liposomes in genetic vaccination. Vaccine 2002;20(Suppl 5):B1-9
112. Mazumder S, Ravindran R, Banerjee A, Ali N. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine 2007;25:8771-81
113. Jaafari MR, Badiee A, Khamesipour A, et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007;25:6107-17
114. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. Biodrugs 2007;21:387-401
115. Christensen D, Korsholm KS, Rosenkrands I, et al. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007;6:785-96
116. Zhang WW, Matlashewski G. Immunization with Toll-like receptor 7/8 agonist vaccine adjuvants increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 2008; In press
117. Mahor S, Gupta PN, Rawat A, Vyas SP. A needle-free approach for topical immunization: antigen delivery via vesicular carrier system(s). Curr Med Chem 2007;14:2898-910
118. Moyle PM, McGeary RP, Blanchfield JT, Toth I. Mucosal immunization: adjuvants and delivery systems. Curr Drug Deliv 2004;1:385-96